Ilveskoski Erkki, Viiri Leena E, Mikkelsson Jussi, Pörsti Ilkka, Lehtimäki Terho, Karhunen Pekka J
Department of Cardiology, Medical School, University of Tampere and Heart Center, Tampere University Hospital, Tampere, Finland.
Atherosclerosis. 2008 Aug;199(2):445-50. doi: 10.1016/j.atherosclerosis.2007.10.021. Epub 2007 Dec 4.
Neuropeptide Y (NPY) has a single nucleotide polymorphism at T1128C, leading to change of Leucine7 to Proline7. The Leu7Pro substitution has been linked to cardiovascular disease, but it is unknown whether the Pro7 allele is associated with increased or decreased risk of coronary heart disease (CHD). The aim of the present study was to investigate the association of the Leu7Pro polymorphism with coronary atherosclerosis and its consequences.
We studied two autopsy series comprising 700 unselected middle-aged Caucasian men (Helsinki Sudden Death Study) who had died suddenly out of hospital. Areas of coronary artery atherosclerosis, narrowings of coronary arteries, and presence of myocardial infarction and/or coronary thrombosis were analyzed. All information including CHD risk factor data was obtained from 410 men.
NPY genotype distribution was Leu7/Leu7=89.8%, Leu7/Pro7=10.0% and Pro7/Pro7=0.2%). Although the Pro7 allele was associated with reported hypertension (p=0.03), the men carrying Pro7 allele had lower area of fatty streaks (p=0.04), fibrotic lesions (p=0.07) and complicated lesions (p=0.004) in the left anterior descending (LAD) coronary artery and also less severe LAD narrowings (p=0.04) than men with the Leu7/Leu7 genotype. Supporting a protective role for the Pro7 allele against atherosclerosis, only 1 out of 46 men (2%) with coronary thrombosis carried the Pro7 allele (p=0.08 compared to men dying of other causes). This association weakened (OR 0.18 for Pro7 versus Leu7/Leu7, p=0.16) when adjusted for all available CHD risk factors.
NPY Pro7 substitution protects middle-aged men from coronary artery atherosclerosis and might decrease the risk of acute coronary events.
神经肽Y(NPY)在T1128C处存在单核苷酸多态性,导致亮氨酸7变为脯氨酸7。亮氨酸7脯氨酸替换与心血管疾病有关,但脯氨酸7等位基因与冠心病(CHD)风险增加或降低是否相关尚不清楚。本研究的目的是调查亮氨酸7脯氨酸多态性与冠状动脉粥样硬化及其后果之间的关联。
我们研究了两个尸检系列,包括700名未经过筛选的中年白种男性(赫尔辛基猝死研究),他们均在院外突然死亡。分析了冠状动脉粥样硬化区域、冠状动脉狭窄情况以及心肌梗死和/或冠状动脉血栓形成情况。所有信息包括冠心病危险因素数据均来自410名男性。
NPY基因型分布为亮氨酸7/亮氨酸7 = 89.8%,亮氨酸7/脯氨酸7 = 10.0%,脯氨酸7/脯氨酸7 = 0.2%。虽然脯氨酸7等位基因与报告的高血压相关(p = 0.03),但携带脯氨酸7等位基因的男性在左前降支(LAD)冠状动脉中的脂肪条纹面积(p = 0.04)、纤维化病变(p = 0.07)和复杂病变(p = 0.004)较小,且LAD狭窄程度也比亮氨酸7/亮氨酸7基因型的男性轻(p = 0.04)。支持脯氨酸7等位基因对动脉粥样硬化具有保护作用的是,46名患有冠状动脉血栓形成的男性中只有1名(2%)携带脯氨酸7等位基因(与死于其他原因的男性相比,p = 0.08)。在对所有可用的冠心病危险因素进行调整后,这种关联减弱(脯氨酸7与亮氨酸7/亮氨酸7相比,OR为0.18,p = 0.16)。
NPY脯氨酸7替换可保护中年男性免受冠状动脉粥样硬化影响,并可能降低急性冠状动脉事件的风险。